Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door to more stable, selective ADCs with application beyond the class’s traditional scope.
Experts discussed the opportunities and challenges of linker innovation as part of a panel at the 2025 CPHI conference, which took place 28–30 October in Frankfurt, Germany. By engineering the molecular make-up of these proteins, they said that new ADCs are being developed able to carry previously unexplored drug payloads with improved stability and more ta